Robust quantitative assessments of cytosine modifications and changes in the expressions of related enzymes in gastric cancer

Gastric Cancer

Volumn 18, Issue 3, 2015, Pages 516-525

  Du, Chunping ^a   Kurabe, Nobuya ^a   Matsushima, Yoshitaka ^a,d   Suzuki, Masako ^a   Kahyo, Tomoaki ^a   Ohnishi, Ippei ^a,b   Tanioka, Fumihiko ^b   Tajima, Shogo ^a,c   Goto, Masanori ^a,e   Yamada, Hidetaka ^a   Tao, Hong ^a   Shinmura, Kazuya ^a   Konno, Hiroyuki ^a   Sugimura, Haruhiko ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Iwata City Hospital   (Japan)

^c SHIZUOKA SAISEIKAI GENERAL HOSPITAL   (Japan)

^d TOKYO UNIVERSITY OF AGRICULTURE   (Japan)

^e NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Adductomics; Cytosine modification; Liquid chromatography mass spectrometry; Ten eleven translocation family genes; D2 5 hmC

Indexed keywords

5 CARBOXYLDEOXYCYTIDINE; 5 FORMYLDEOXYCYTIDINE; 5 HYDROXYMETHYLDEOXYCYTIDINE; 5 METHYLDEOXYCYTIDINE; CYTOSINE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; UNCLASSIFIED DRUG; 5-FORMYL-2'-DEOXYCYTIDINE; 5-HYDROXYMETHYL-2'-DEOXYCYTIDINE; 5-HYDROXYMETHYLCYTOSINE; 5-METHYLDEOXYCYTIDINE; DEOXYCYTIDINE; DIOXYGENASE; DNA BINDING PROTEIN; ENZYME; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; ONCOPROTEIN; TET1 PROTEIN, HUMAN; TET2 PROTEIN, HUMAN; TET3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE LOSS; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IDH1 GENE; IDH2 GENE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; TANDEM MASS SPECTROMETRY; TDG GENE; TET1 GENE; TET2 GENE; TET3 GENE; TUMOR GENE; ANALOGS AND DERIVATIVES; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; METABOLISM; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH TUMOR;

AGED; CHROMATOGRAPHY, LIQUID; CYTOSINE; DEOXYCYTIDINE; DIOXYGENASES; DNA-BINDING PROTEINS; ENZYMES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS; STOMACH NEOPLASMS; TANDEM MASS SPECTROMETRY;

EID: 84938963871     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-014-0409-4     Document Type: Article

References (36)

1. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324:930–5.
2. Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science. 2009;324:929–30.
3. Ito S, D’Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature. 2010;466:1129–33.
4. He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science. 2011;333:1303–7.
5. Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 2010;102:932–41.
6. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19:17–30.
7. Jin SG, Jiang Y, Qiu R, Rauch TA, Wang Y, Schackert G, et al. 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res. 2011;71:7360–5.
8. Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J, et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene. 2013;32:663–9.
9. Kraus TF, Globisch D, Wagner M, Eigenbrod S, Widmann D, Munzel M, et al. Low values of 5-hydroxymethylcytosine (5hmC), the “sixth base,” are associated with anaplasia in human brain tumors. Int J Cancer. 2012;131:1577–90.
10. Hsu CH, Peng KL, Kang ML, Chen YR, Yang YC, Tsai CH, et al. TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep. 2012;2:568–79.
11. Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell. 2012;150:1135–46.
12. Yang Q, Wu K, Ji M, Jin W, He N, Shi B, et al. Decreased 5-hydroxymethylcytosine (5-hmC) is an independent poor prognostic factor in gastric cancer patients. J Biomed Nanotechnol. 2013;9:1607–16.
13. Association Japanese Gastric Cancer. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.
14. Lauren P. The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification. Acta Pathol Microbiol Scand. 1965;64:31–49.
15. Oshima H, Matsunaga A, Fujimura T, Tsukamoto T, Taketo MM, Oshima M. Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. Gastroenterology. 2006;131:1086–95.
16. Globisch D, Munzel M, Muller M, Michalakis S, Wagner M, Koch S, et al. Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. PLoS One. 2010;5:e15367.
17. Sumino M, Ohkubo A, Taguchi H, Seio K, Sekine M. Synthesis and properties of oligodeoxynucleotides containing 5-carboxy-2’-deoxycytidines. Bioorg Med Chem Lett. 2008;18:274–7.
18. Nomura Y, Haginoya N, Ueno Y, Matsuda A. Nucleosides and nucleotides. 161. Incorporation of 5-(N-aminoalkyl)carbamoyl-2′-deoxycytidines into oligodeoxyribonucleotides by a convenient post-synthetic modification method. Bioconjug Chem. 1996;6:2811–6.
19. Itahara T. Oxidation of Cytosine and 5-Methylcytosine Nucleosides and 5-Methyl-2’-deoxycytidine 5’-Monophosphate with Peroxosulfate Ions. Chem Lett. 1991;1591-4.
20. Ismael O, Shimada A, Hama A, Sakaguchi H, Doisaki S, Muramatsu H, et al. Mutations profile of polycythemia vera and essential thrombocythemia among Japanese children. Pediatr Blood Cancer. 2012;59:530–5.
21. Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, et al. Recurrent R-spondin fusions in colon cancer. Nature. 2012;488:660–4.
22. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487:239–43.
23. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012;486:400–4.
24. Liu S, Wang J, Su Y, Guerrero C, Zeng Y, Mitra D, et al. Quantitative assessment of Tet-induced oxidation products of 5-methylcytosine in cellular and tissue DNA. Nucleic Acids Res. 2013;41:6421–9.
25. Cadet J, Wagner JR. TET enzymatic oxidation of 5-methylcytosine, 5-hydroxymethylcytosine and 5-formylcytosine. Mutat Res. 2013;
26. Ivanov M, Kals M, Kacevska M, Barragan I, Kasuga K, Rane A, et al. Ontogeny, distribution and potential roles of 5-hydroxymethylcytosine in human liver function. Genome Biol. 2013;14:R83.
27. Minor EA, Court BL, Young JI, Wang G. Ascorbate induces ten-eleven translocation (Tet) methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine. J Biol Chem. 2013;288:13669–74.
28. Coulter JB, O’Driscoll CM, Bressler JP. Hydroquinone increases 5-hydroxymethylcytosine formation through ten eleven translocation 1 (TET1) 5-methylcytosine dioxygenase. J Biol Chem. 2013;288:28792–800.
29. Briere JJ, Favier J, Benit P, El Ghouzzi V, Lorenzato A, Rabier D, et al. Mitochondrial succinate is instrumental for HIF1alpha nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions. Hum Mol Genet. 2005;14:3263–9.
30. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005;7:77–85.
31. Shi Y. Histone lysine demethylases: emerging roles in development, physiology and disease. Nat Rev Genet. 2007;8:829–33.
32. Da Costa NM, Hautefeuille A, Cros MP, Melendez ME, Waters T, Swann P, et al. Transcriptional regulation of thymine DNA glycosylase (TDG) by the tumor suppressor protein p53. Cell Cycle. 2012;11:4570–8.
33. Xu X, Yu T, Shi J, Chen X, Zhang W, Lin T, et al. Thymine DNA glycosylase is a positive regulator of Wnt signaling in colorectal cancer. J Biol Chem. 2014
34. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360:2289-301.
35. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2011;39:D945–50.
36. Balbo S, Turesky RJ, Villalta PW. DNA adductomics. Chem Res Toxicol. 2014